SureTrader Stock Hero Advertisement SureTrader
Home > Boards > US OTC > Medical - Drugs >

Ocata Therapeutics Inc. (OCAT)

OCAT RSS Feed
Add OCAT Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator elysse1kittycat, sports guy, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 5/25/2015 9:15:04 AM - Followers: 642 - Board type: Free - Posts Today: 7


 Ocata Therapeutics (OCAT)

formerly Advanced Cell Technology (ACTC):
Advanced Cell Technology Changes Name to Ocata Therapeutics

https://www.ocata.com/
 

Ocata Therapeutics Headquarters
33 Locke Drive
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333
info@ocata.com 
 

Company Overview

Ocata Therapeutics, Inc. (“Ocata”; OTCBB: OCAT), formerly named Advanced Cell Technology, is a clinical stage biotechnology company focused on the development and commercialization of new therapies in the field of regenerative medicine. Regenerative medicine is defined as the process of replacing or regenerating human cells, tissues or organs to restore or establish normal function and has been called the “next evolution of medical treatments” and “the vanguard of 21st century healthcare” by the U.S. Department of Health and Human Services.

The company’s principal R&D and commercial efforts relate to its Regenerative Ophthalmology™ programs and involve development of therapies for the treatment of eye diseases and disorders. Beyond the eye, our other research areas include projects focusing on developing many different cell therapies that may be used to treat a range of diseases across several therapeutic categories. Ocata’s principal laboratory, GMP facility and corporate offices are in Marlborough, Massachusetts. 
 

Regenerative Ophthalmology Platform

The mission behind our Regenerative Ophthalmology efforts is clear. It is our goal to bring innovative new therapies to the market to treat diseases of the eye that otherwise may cause significant loss of vision in patients. Our emerging cell therapies focus on structural repair and functional restoration and have the potential to make a significant difference in the lives of people with ocular disorders.

We are at the forefront of developing new therapies to address some of the most significant unmet medical needs in eye diseases. These include potential treatments for diseases affecting the retina, such as age-related macular degeneration – as well as other forms of macular degeneration, diabetic retinopathy and retinitis pigmentosa, as well as inflammatory diseases such as uveitis, and vision loss from photoreceptor and other neurosensory retinal damage due to glaucoma.

  • Our lead clinical program involves RPE Cell Therapy for treating macular degeneration. Critical to the development and the rate of progression of macular degeneration is the health status of the retinal pigment epithelium, or RPE, a single layer of cells whose presence and integrity in the retina are required for normal vision. The company is currently conducting clinical trials in the U.S. andU.K. for treating Stargardt’s macular degeneration with the RPE Cell Therapy, and in the U.S. for treating patients with dry age-related macular degeneration.
    We are developing a Photoreceptor Progenitor Cell Therapy which we intend to be used for treating a wide variety of retinal degenerations in diseases where photoreceptors malfunction and/or die.
    Our Ganglion Progenitor Cell Therapy is a preclinical candidate program. In animal models of glaucoma, the injection of these cells protects against damage of existing nerve cells as well as forms new ganglion nerve cells.
    The company is also developing therapeutic platforms using Corneal Endothelial Cells for use in treating corneal blindness.

See our Pipeline of Ophthalmology Therapies »


Other Regenerative Medicine Programs

In addition to our regenerative ophthalmology programs we have invested in other programs where we feel that we can leverage our expertise in cellular and developmental biology to generate allogeneic therapies that have the potential to improve health care in other prevalent degenerative diseases and diseases of aging. At the core of our pipeline planning are approaches intended to address large unmet medical needs with allogeneic stem cell-derived therapeutics.

Our Mesenchymal Stem Cells

Our Mesenchymal Stem Cells (MSCs) represent an “off-the-shelf” cellular therapy ready for treatment of autoimmune and inflammatory diseases in both acute and chronic settings. MSCs regulate immune and inflammatory responses, providing therapeutic potential for treating diseases characterized by the presence of an inflammatory component, which makes them an attractive tool for the cellular treatment of autoimmunity and inflammation. We believe we have succeeded at creating a differentiated MSC product by producing the cells in culture from a pluripotent stem cell source.

Neuroprotective Biologics

We have discovered Neuroprotective Biologics that are secreted by certain of our neurosensory retina progenitor cell populations. We anticipate that the neuroprotective agent(s) that we may ultimately develop as drug candidates may be useful not only in retinal diseases and dystrophies, but may have broader applications in central nervous system and peripheral nervous system diseases and disorders, including diseases causing cognitive function impairment, movement disorders such as Parkinson’s Disease, and ischemic events such as caused by stroke.

Blood Components Programs

Through our Blood Components Programs, we have been able to generate Red Blood Cells, Platelets, Dendritic cells and other cells relevant immune response or hemostasis.

 

Pipeline of Therapeutic Programs

Ocata’s world-class research and development programs embody our efforts to bring transformative new therapies to market for patients facing some of hardest-to-treat eye diseases and disorders.

Filings:

http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001140098&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany
 

 

 


Press Releases

 

 

 

 



 


All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

 

 

Rules of the board according to IHUB:
http://www.investorshub.com/boards/complex_terms.asp


 

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
OCAT
Current Price
Volume:
Bid Ask Day's Range
Wiki
PostSubject
#76767  Sticky Note Ocata Therapeutics Receives Advanced Therapy Medicinal Product Designation lasers 11/24/14 12:12:44 PM
#74805  Sticky Note ACT Announces Positive Results from Two Clinical Trials LittleDutchDenny 10/14/14 09:50:43 PM
#84669   LOL LOL !! Quote, "LOL Quote in Ref. Captain Kirk 05/25/15 09:15:04 AM
#84668   Kinda hard to make sense of the post farviewhill 05/25/15 09:05:16 AM
#84667   I am not saying that SOME DAY if elysse1kittycat 05/25/15 08:49:52 AM
#84666   LOL Quote in Ref. to Bluebird... It Trader Joey 05/25/15 07:58:36 AM
#84665   The Moving Averages Have Converged Forming A DoubleHelix! rumper 05/25/15 07:01:01 AM
#84664   How fast did this shareprice go to $27...? Quick? chuckanutman 05/25/15 01:31:40 AM
#84663   So lets see-if I read this correctly, by elysse1kittycat 05/25/15 12:47:29 AM
#84662   This post keeps coming up on OCAT internet-search. chuckanutman 05/24/15 11:22:14 PM
#84661   That doesn't sound at all to me like farviewhill 05/24/15 10:58:13 PM
#84660   If one wants to read between the lines elysse1kittycat 05/24/15 10:34:09 PM
#84659   As a general rule I am sure you elysse1kittycat 05/24/15 10:22:03 PM
#84658   A constructive response, rather than sarcasm, would prove farviewhill 05/24/15 10:00:11 PM
#84657   Good to see confirming OCAT science. chuckanutman 05/24/15 09:59:55 PM
#84656   LOL quote, "Then you don't know about Bluebird Captain Kirk 05/24/15 08:58:46 PM
#84655   I tentatively agree, but we'll have to see OcataMattaDingDong 05/24/15 08:53:43 PM
#84654   He never said he "liked" OCAT. He said OcataMattaDingDong 05/24/15 08:51:06 PM
#84653   Elysse, Then they are delusional because individual investors do OcataMattaDingDong 05/24/15 08:46:36 PM
#84652   This is the main reason I am in OcataMattaDingDong 05/24/15 08:44:46 PM
#84651   Well, I don;t really see it as an OcataMattaDingDong 05/24/15 08:43:19 PM
#84650   Yeah but individual investors don't have the money OcataMattaDingDong 05/24/15 08:41:10 PM
#84649   Yes to everything. It's a very speculative and OcataMattaDingDong 05/24/15 08:31:24 PM
#84648   Then you don't know about Bluebird Bio and OcataMattaDingDong 05/24/15 08:27:36 PM
#84647   It didn't have anything at all about "liking" OcataMattaDingDong 05/24/15 08:22:33 PM
#84646   Yeah it's good he knows what they are OcataMattaDingDong 05/24/15 08:17:14 PM
#84645   <LOL> No, you're definitively wrong. You said, "What? Huh? OcataMattaDingDong 05/24/15 08:03:01 PM
#84644   I am sure that there is a lot elysse1kittycat 05/24/15 07:13:01 PM
#84643   Good to hear your apparent intent to cut elllk 05/24/15 06:49:31 PM
#84641   KIRK's and Ding Dong are 'gifts' if you farviewhill 05/24/15 06:13:31 PM
#84640   elllk 05/24/15 05:39:01 PM
#84638   chuck called your bluff, OMDD. That vimeo from north40000 05/24/15 05:02:11 PM
#84636   Quote FALSE LOL, "The Biotech history, very clearly Captain Kirk 05/24/15 04:24:11 PM
#84634   The Biotech history, very clearly shows phase2 runs-run. chuckanutman 05/24/15 04:11:17 PM
#84633   I Like Ocata Because Their RPE Therapy Works!!! Real_Good! rumper 05/24/15 04:09:31 PM
#84632   Biotech history, very clearly shows that any significant farviewhill 05/24/15 04:05:47 PM
#84630   Question, please. farviewhill 05/24/15 03:43:48 PM
#84628   LOL quote, "GE HealthCare Chief Dr. Steven Minger Captain Kirk 05/24/15 03:02:27 PM
#84627   "quote of OCAT's lifetime". chuckanutman 05/24/15 01:59:54 PM
#84626   Keeping on keeping on. "persistence". Key to success. chuckanutman 05/24/15 01:50:44 PM
#84625   Still holding and buying OCAT when I LODE MAKING ME RICH 05/24/15 01:33:32 PM
#84622   Personally I think the name of the Icell elysse1kittycat 05/24/15 11:35:43 AM
#84620   Quote LOL, "Ownership of OCAT shares. From Stemvest Captain Kirk 05/24/15 11:02:50 AM
#84619   LOL, WRONG DingDong, I didn't miss a thing Captain Kirk 05/24/15 10:50:16 AM
#84618   Ownership of OCAT shares. From Stemvest of Icell: chuckanutman 05/24/15 10:12:19 AM
#84617   All I know is that over the nine elysse1kittycat 05/24/15 09:38:25 AM
#84615   Its clear ... runcaly 05/24/15 08:24:10 AM
#84614   GEHC-Chief Dr. Steven Minger truely likes ACT/OCAT. All chuckanutman 05/24/15 01:42:35 AM
#84613   GEHC-Chief Dr. Steven Minger truely likes ACT/OCAT. All chuckanutman 05/24/15 01:25:49 AM
#84612   The Minger / OCAT rumor makes it's rounds OcataMattaDingDong 05/24/15 01:20:13 AM
#84611   If Minger didn't actually say that on this elysse1kittycat 05/24/15 01:15:49 AM
#84610   Would you link to that quote please, because OcataMattaDingDong 05/24/15 01:02:21 AM
PostSubject